---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-032091"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-07-06T13:00:15+00:00"
generated_at: "2026-07-06T13:01:14.883592+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MIRA's SKNY-1 shows favorable oral bioavailability, brain penetration in preclinical studies

## Summary
- Optimized oral formulation of SKNY-1 demonstrated favorable oral bioavailability and reproducible systemic exposure in preclinical PK study.
- Robust brain penetration and substantial liver exposure observed; peak plasma concentrations at 6-12 hours support once-daily oral dosing.
- Findings complement prior efficacy studies showing weight reduction, lean mass preservation, and reduced compulsive feeding/nicotine-seeking.
- SKNY-1 designed with biased CB1 modulation, CB2 agonism, and selective MAO-B inhibition; no anxiety-like behavior in preclinical model.

## SEC filing metadata
- accession: 0001493152-26-032091
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-07-06T13:00:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226032091/0001493152-26-032091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226032091/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-032091
- JSON: https://secwatch.observer/filing/0001493152-26-032091.json
- Plain text: https://secwatch.observer/filing/0001493152-26-032091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.